Comparing tumor markers in stomach and esophagus cancers that spread to the brain
Original title: Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed, and this study looks at stored tissue samples.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study checks if a brain tumor carries the same markers as the cancer it came from.
Who this trial is for. This study is for people with cancer of the esophagus, the stomach, or the junction where they meet, that has spread to the brain. It uses stored tissue from the first tumor and from the matching brain tumor, drawn from an earlier group of over 230 patients.
Where it stands. This study has not reported results. The team is testing four markers in each pair of samples: HER2, MSI, PD-L1, and CLDN18.2. They want to see how closely the brain tumor matches the first tumor. The answer is not in yet.
What this means, and what it doesn't
What it could mean: This work may show whether testing the first tumor tells the whole story for a brain tumor. That is useful to know, but it is a question, not an answer. If this fits your situation, you can ask your care team about it.
What it doesn't mean: This does not mean a new treatment is ready. A study is a test, not proven care. Taking part in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, October 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.